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Background: Local control appears to be an important treatment aim in patients with limited metastases
(oligometastases) of colorectal cancer (CRC). Those patients show a favourable prognosis, if - in addition to the local
effective treatment - an occurrence of new metastases may also be postponed by effective systemic therapy. The
purpose of this dose escalation phase I study was to establish the efficacy of local radiotherapy (RT) of
oligometastatic CRC with a concurrent standard chemotherapy regimen.
Methods: Patients with first-, second- or third-line therapy of oligometastatic CRC (1–3 metastases or local
recurrence plus max. 2 metastases) received capecitabine (825 mg/m2/d BID d 1–14; 22–35) and oxaliplatin (50 mg/
m2 d 1, 8, 22, 29). 3D-conformal RT of all metastatic lesions was delivered in 2.0 Gy up to 36 Gy to 50 Gy (3 dose
levels). Primary endpoint was the maximal tolerable dose (MTD) of RT defined as the level at which two or more of
six patients experienced dose-limiting toxicity (DLT).
Results: Between 09/2004 and 08/2007, 9 patients (7 male, 2 female, 50–74 years) were enrolled, 6 patients treated
at dose level 1 (36 Gy), 3 patients at dose level 2 (44 Gy). 1 patient from the first cohort experienced DLT
(oxaliplatin-related hypersensitivity reaction). No radiation-induced DLT occurred. 6/9 patients achieved objective
response (partial remission). One year after initiation, all patients were alive, 6 patients survived (16 to 54 months)
patients died of tumor progression (14 to 23 months). The phase II part of the trial had to be closed due to
recruitment failure.
Conclusions: Local 3D-CRT to metastatic lesions in addition to standard chemotherapy was feasible, DLT was not
documented. 3/9 patients survived for a period of 3.5 to 4.4 years (time at the last evaluation). Radiotherapy of
metastatic lesions should be incorporated into subsequent trials.
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Colorectal cancer is one of the most common cancer
diagnosis among both genders and with an estimated
number of 207 400 (12.2%) of total deaths the second
major cause of cancer death in Europe in 2006 [1]. At
the time of diagnosis about 25% of patients present with
metastases and more than one third of patients will* Correspondence: kathrin.dellas@uksh.de
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provided the original work is properly cited.develop metastatic disease after curative resection of the
primary tumor in the further course of disease, mainly
liver metastases.
Patients with a single or few liver or lung metastases
should undergo curative intended resection of their me-
tastases and have a chance of long-term cure in the
range of 30 to 40% [2]. In irresectable metastases, pallia-
tive chemotherapy aims to prolong survival while pre-
serving or improving the quality of life. However,
definition of a potentially curative and a palliative ap-
proach has therefore been mainly determined byticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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surgical local ablative therapies have been developed,
and the question was raised whether a subset of patients
with a limited number of metastases (oligometastatic
disease) might benefit from the addition of such local
therapy to systemic chemotherapy.
Local efficacy of radiotherapy has been well documen-
ted in mCRC and palliative radiotherapy can be used ef-
fectively for controlling symptoms [3-8]. Though
improved diagnosis and therapy planning also multiple
lesions can be localized exactly and irradiated in small
volume, respectively. A requirement for this is also a
planning target definition adapted to the metastases.
The combinations of oxaliplatin with capecitabine have
shown both, efficacy in mCRC as systemic treatment
and radiosensitizing potential [9-15], and are therefore
suitable from a radiobiological point of view particularly
for the combination with radiotherapy. The application
can be used concurrently with radiotherapy, without in-
creasing toxicity of the chemotherapy or radiotherapy
considerly.
Therefore, the purpose of this dose escalation phase I
study was to establish a regimen of local radiotherapy
with concurrent standard chemotherapy in oligometa-
static colorectal cancer.
Patients and methods
The study was conducted according to the principles of
the Declaration of Helsinki and to good clinical practice
guidelines. The Ethics Committee, University of Halle,
approved this study. Each patient gave written informed
consent before being included.
Eligibility criteria
The eligibility criteria included histopathologically con-
firmed oligometastatic colorectal cancer (1–3 metastases
with largest diameter 5 cm or local recurrens of rectal
cancer plus 1–2 metastases of ≤ 5 cm in technically or
clinically irresectable disease, extention to the recruit-
ment of patients in a neoadjuvant situation (before
planned resection). Patients with first-, second- or third-
line therapy of oligometastatic colorectal cancer were
eligible for this study in adequate renal, hepatic and
hematologic function. Additional inclusion criteria were
age ≥ 18 years, Karnofsky performance status ≥ 70%,
creatinin clearance> 30 mL/min calculated according to
Cockroft and Gault, total bilirubin concentration less
than 2.5 and transaminases less than 2.5 times the upper
normal limit with hepatic metastases after image-guided
exclusion of intra- or extrahepatic cholestasis and trans-
aminases less than 5.0 times the upper normal limit,
neutrophils> 2.5 x 109/L, platelet count> 125 x 109/L,
estimated life expectancy of more than 3 months, writ-
ten informed consent and tumor assessment analyzedaccording to “Response Evaluation Criteria in Solid
Tumors” (RECIST).
Key exclusion criteria included previously adminis-
tered radiotherapy not allowing the required dose, sig-
nificant cardiac disease (heart failure NYHA III-IV,
myocardial infarction within the last three months or
symptomatic heart disease) and cerebrovascular disor-
ders thought to adverse-affects treatment compliance.
Patients with the following conditions were also ineli-
gible: serious, uncontrolled infections, malabsorption
syndrome, known sensitivity to fluoropyrimidines and
dihydropyrimidine dehydrogenase deficiency, allergy to
platin derivative, peripheral neuropathy, current treat-
ment with sorivudin or bivudin and treatment history of
other cancer or participation in another clinical trial
within 4 weeks of the start of treatment. Pregnant or lac-
tating patients and women with childbearing potential
who lacked a reliable contraceptive method were also
excluded.
Study design and treatment
We undertook a prospective, single center phase I study.
The primary endpoint was to determine the maximal
tolerable dose (MTD) and dose-limiting toxicity (DLT)
of chemoradiotherapy with concurrent 3D-radiotherapy
to all (max. 3) metastatic lesions. Radiation dose levels
of all metastatic leasions were the planned dose levels at
36 Gy, 44 Gy and 50 Gy in 2.0 Gy daily fractions (as
described later, the dose level at 50 Gy was not reached).
The secondary endpoints included the evaluation of
antitumor activity of the combined-modality treatment
in objective response according to the Response Evalu-
ation Criteria In Solid Tumors (RECIST) [16] (rate of
complete or partial remission), time to progression,
overall survival (one year survival rate) and toxicity.
During radiotherapy, capecitabine was administered
with a fixed dose (825 mg/m2/d orally BID on days 1–14
and 22–35), and oxaliplatin (50 mg/m2 as 2 h infusion
on days 1, 8, 22 and 29). After completion of chemora-
diation, systemic treatment could be continued in stand-
ard dosage (capecitabine 1000 mg/m2/d orally BID on
days 1–14 and oxaliplatin 70 mg/m2 infusional on days
1 and 8). Staging was completed in the third week of the
third cycle (week 9), and therapy was considered to con-
tinue at the physician’s discretion.
The following recommendations for dose reductions
were applied: if one patient experienced grade 1 toxicity
(according to National Cancer Institute Common Tox-
icity Criteria version 3.0) considered to be possibly
related to radiation, treatment was continued, with ap-
propriate prophylactic treatment. In case of grade 2 tox-
icity, radiation treatment was continued for one week at
maximum. If patient experienced any grade 2 toxicity
for more than one week or more severe intensity,








Male 4 3 7
Female 2 - 2
Age, years
MW 63.2 65.3 63.9
SD 10.1 5.0 8.4
Karnofsky performance status (%)
MW 93.3 96.7 94.4
SD 8.2 5.8 7.3
Pathologic staging (at the time of accrural)
T T0 4 3 7
T4 2 - 2
N N0 5 3 8
N1 1 - 1
M M0 1 - 1
M1 5 3 8
MW: Mean, SD: Standard deviation.
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resolved to grade 1, treatment was resumed, if possible.
Interruption or conduction of radiation may be related
to one or several planning target volumes. In case of re-
currence of toxicity while continuing radiation, which
would require further discontinuation of radiation ther-
apy (as defined above) radiation of this planning target
volume was permanently discontinued. Radiotherapy
was considered to be in accordance with the protocol if
at least 80% of the planed dosage for the planning target
volume was applied and therapy was no longer discon-
tinued than for 7 days.
3D-CRT technique
A total irradiation dose of 36 Gy or 44 Gy was delivered
in 2.0 Gy daily fractions, Monday through Friday. In this
protocol, high-energy photons (6 to 15 MeV) were used
and three-dimensional planning with measurements of
macroscopic tumor, planning target volume and organs
at risk were mandatory. All lesions had to be defined by
computed tomography clearly. The clinical target vol-
ume (CTV) was the GTV of each lesion. Planning target
volume contained all detectable metastases was derived
by adding a margin of 10 mm to account the CTV for
the setup uncertainties. It was required that the 90%-
isodose line covered the planning target volume. Two
metastatic lesions could be integrated into one planning
target volume if they were located close to each other.
Evaluation of safety and efficacy
Adverse events were graded to National Cancer Institute
of Canada (NCIC) Common Toxicity Criteria (CTC)
(revised in May 1991). Dose-limiting toxicity (DLT) was
defined as the occurrence of any grade three and four
toxicity, except alopecia, hematologic toxicity and transi-
ent elevation of transaminases. Within the three dose
levels, dose escalation of radiation was performed with
the same dose of chemotherapy. According to potentially
different toxicity at different sites of metastatic lesions,
modified rules for escalation were used: Three patients
had to be enrolled per predefined dose level. If there was
no DLT in the first three patients, the cohort was
extended by another three patients at the same dose
level, to obtain sufficient safety profile associated with
different toxicity depending on multiple metastatic
lesions.
The safety analysis included all patients who received
at least one dose (one day) of radiation and chemother-
apy. All adverse events were monitored continuously
during treatment and observed until decreasing or
stabilization of symptoms. Hematology and clinical
chemistry was performed weekly during treatment and
thereafter during chemotherapy weekly, respectively
after every third cycle, after the end of chemotherapyand during follow up every three months. Tumor assess-
ment was initiated on the basis of RECIST criteria 1.0 at
baseline, within 14 days before the start of treatment,
and after the end of the combined treatment.
Statistical aspects
A modified escalation design with three to six patients
was chosen on empiric grounds, according to current
standards in phase I cancer trials. According to the ex-
ploratory nature of this pilot trial, only descriptive statis-
tical methods are used, giving rates, means with SD, and
quartiles and ranges.
Results
A total of nine patients were enrolled (seven male and two
female patients between 50 and 74 years of age) into the
study at Halle University between September 2004 and Au-
gust 2007 (Table 1). Before including into the study, six
patients had been previously treated with radiotherapy at
other sites, and all of the nine patients received previously
chemotherapy and surgery. In three patients, systemic pre-
treatment was administered as capecitabine and oxaliplatin,
one patient received capecitabine, oxaliplatin, 5-FU and leu-
covorin, one patient received 5-FU and leucovorin, one pa-
tient received 5-FU and oxaliplatin, one patient was treated
with 5-FU, leucovorin, oxaliplatin and irinotecan, one pa-
tient was treated with 5-FU, leucovorin, capecitabine, oxali-
platin, irinotecan and cetuximab and one patient received
5-FU, leucovorin, irinotecan and bevacizumab. Issued by
the criteria for inclusion the metastatic lesions were not
Table 2 Incidence and maximum severity of toxicities
(MedDRA classification)
Dose level 1 Dose level 2
P
CTC grade 1/2 3 4 1/2 3 1/234
MedDRA Code (n = 9 events) No. of Patients
Infections and infestations
Infection 0 2 0 0 0 0 20
Immune system disorders
Anaphylactic reaction 0 0 1 0 0 0 01
Nervous system disorders
Peripheral sensory neuropathy 2 0 0 1 0 3 00
Eye disorders
Conjunctival haemorrhage 1 0 0 0 0 1 00
Vision blurred 1 0 0 0 0 1 00
Disorder sight 1 0 0 0 0 1 00
Abnormal sensation in eye 1 0 0 0 0 1 00
Vascular disorders
Flushing 2 0 0 0 0 2 00
Hypotension 1 0 0 1 0 2 00
Thrombophlebitis 1 0 0 0 0 1 00
Respiratory, thoracic and mediastinal disorders
Dyspnoea 0 1 0 0 0 0 10
Gastrointestinal disorders
Abdominal pain 0 0 0 1 0 1 00
Abdominal distension 1 0 0 0 0 1 00
Vomiting 0 0 0 1 0 1 00
Obstipation 2 0 0 0 0 2 00
Mucous stools 1 0 0 0 0 1 00
Nausea 3 0 0 2 0 5 00
Abdominal discomfort 1 0 0 0 0 1 00
Epigastric discomfort 0 0 0 1 0 1 00
Skin and subcutaneous tissue disorders
Dermatitis 1 0 0 2 0 3 00
Musculoskeletal and connective tissue disorders
Bone pain 1 0 0 0 0 1 00
Myalgia 1 0 0 0 0 1 00
Pain in extremity 1 0 0 0 0 1 00
Renal and urinary disorders
Bladder discomfort 2 0 0 0 0 2 00
General disorders and administration site conditions
Injection site erythema 0 0 0 1 0 1 00
Pyrexia 1 0 0 1 0 2 00
Injection site paraesthesia 0 0 0 1 0 1 00
Mucosal inflammation 1 0 0 0 0 1 00
Pain 3 1 0 1 0 4 10
Chills 1 0 0 1 0 2 00
Table 2 Incidence and maximum severity of toxicities
(MedDRA classification) (Continued)
Investigations
Blood amylase increased 1 0 0 0 0 1 00
Blood bilirubin increased 2 0 0 3 0 5 00
Blood pressure increased 0 0 0 2 0 2 00
Blood urea increased 1 0 0 0 0 1 00
Blood urea decreased 0 0 0 2 0 2 00
C-reactive protein increased 4 0 0 1 0 5 00
Blood fibrinogen increased 1 0 0 0 0 1 00
Gamma-glutamyltransferase increased 4 0 0 1 1 5 10
Blood glucose increased 0 0 0 1 0 1 00
Haemoglobin decreased 4 0 0 2 0 6 00
Blood uric acid increased 1 0 0 0 0 1 00
Blood calcium decreased 3 0 0 2 0 5 00
Blood creatinine increased 3 0 0 1 0 4 00
Blood lactate dehydrogenase increased3 0 0 1 0 4 00
WBC count increased 1 0 0 0 0 1 00
WBC count decreased 1 1 0 2 0 3 10
Platelets decreased 3 0 0 2 0 5 00
Transaminases increased 2 0 0 3 0 5 00
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was a single lesion in four patients, two lesions in two
patients and three lesions in three patients (a total of 17
lesions in 9 patients). In seven patients the lesion was
located in the liver and two patients had a non-liver-lesion
(vulva and local recurrence presacral).
Dose escalation and DLT
Initially, three patients were treated at the lowest dose
level of radiation (36 Gy), without dose-limiting toxicity.
According to the study protocol, three additional patients
were included at this dose level. Therefore, six patients
were treated at the lowest dose level one and three
patients at dose level two (44 Gy). The fourth patient
from the first cohort experienced a non-radiotherapy
related DLT (oxaliplatin-related hypersensitivity reac-
tion). There was no DLT in the three patients treated in
the second cohort until the premature termination. No
radiation-induced DLT occurred. The dosage finding
remained incomplete and MTD could not be deter-
mined. The trial had to be closed due to recruitment fail-
ure. There were no safety-related concerns regarding the
premature trial termination.
Hematologic and non-hematologic toxicity
Adverse events according to MedDRA Code CTC sever-
ity grade by body/organ system are presented for the
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was oxaliplatin-related hypersensitivity reaction (one pa-
tient in cohort one), consecutively classified as DLT.
Four patients experienced grade 3 toxicity, three patients
from the first cohort and one patient from the second
dose level. In the three patients at dose level one, grade
3 toxicities occurred (infection, dyspnea, pain and leuco-
cytopenia). Grade 3 toxicity with increasead liver
enzymes was documented in one patient at dose level
two. No instance of radiation-induced liver disease
(RILD) has been observed.
Further hematologic and non-hematologic toxicity was
usually mild (grade 1 and 2). Five patients showed any
increased levels of blood bilirubin, transaminases and C-
reactive protein, six patients an elevation of gamma-
glutamyltransferase and four patients of lactate dehydro-
genase. Low hemoglobin as well as low platelet counts
were seen in six and five patients, respectively.
Gastrointestinal toxicities occurred in five patients con-
sisting primarily of nausea and in two patients with ab-
dominal and epigastric discomfort. Furthermore,
dermatitis was recorded in three patients.
Antitumor activity
Secondary endpoint was the objective tumor response,
defined as the rate of complete or partial remission. A
total of seventeen lesions in nine patients were irra-
diated. Six of nine patients achieved tumor response
(partial remission), for two patients adequate data were
not assessable. Disease progression after one year oc-
curred in three patients (two patients from the first co-
hort, one patient from the second cohort). The first
patient from the first cohort developed new liver metas-
tases and distant metastases (lung lesions). For the sec-
ond patient from the first cohort and the patient from
the second cohort with progressive disease adequate
data were not available. One year after initiation, all
patients were still alive. Within the following year, three
patients died from tumor progression (14 to 23 months
after initiation). At the time of last evaluation four
patients had survived (16 to 54 months after initiation,
Table 3).
Discussions
We conducted this phase I trial as a multimodal regimen
for patients with oligometastatic colorectal cancer,Table 3 Parameters for survival
Dosis 1 Dosis 2
Survived Lost to Follow up Survived
1 year 6 0 3
3 years 3 0 0
One year after initiation all patients were alive, three patients had died of tumor prconsisting of 3D-radiotherapy of all metastatic lesions
with a concurrently administered standard systemic
therapy with capecitabine and oxaliplatin (XELOX regi-
men) [17,18]. The primary objective of this study was to
determine the maximal tolerable dose (MTD) of local
radiotherapy combined with standard chemotherapy.
The study used conventionally fractionated radiotherapy
under the assumption that this treatment is widely avail-
able, safe and effective as known from preoperative
radiotherapy in locally advanced rectal cancer.
Most commonly, local disease control can be assessed
by pathohistological response, which is likely correlated
with relapse free suvival after 5-FU based chemora-
diotherapy. Pathological complete response (pCR) rates
following fluoropyrimidine based chemoradiation have
been reported in 15-20% of patients. Many phase II trials
indicate, that the rate of pathohistologic response (pCR)
of the local tumor may be improved by adding highly ef-
fective substances like oxaliplatin, combined with 5-FU
or capecitabine - an emerging strategy in the multimod-
ality management of locally advanced rectal cancer [19].
In preoperative chemoradiation for localized rectal can-
cer, phase II and III trials have shown that the combin-
ation of radiation with capecitabine and oxaliplatin
shows moderately high rates of histopathological eradi-
cation of the tumor. Data of phase II trials suggests a
pCR rate up to the above mentioned 20%, whereas rates
in phase III trials only showed “borderline” significant
improvement [12-15]. The arguments for a regimen of
chemoradiation, based on capecitabine, oxaliplatin and
radiation, are the efficacy of the chemoradiation, radio-
sensitizing potential and the approved feasibility of the
mentioned combined regimen in terms of systemic ac-
tivity. However, the final prove of effectiveness of adding
oxaliplatin to the preoperative therapy is still under in-
vestigation, but reported preliminary results from phase
III trials, the French ACCORD study [12], the Italian
STAR-01 study [15] as well as the US NSABP R-04 trial
[14] did not show a significant increased rate of pCR´s,
and in the German phase III trial, only a small incre-
ment was documented [13]. It has to be shown, whether
these results impact on lead to improved local failure or
distant metastases.
We aimed to evaluate the efficacy and feasibility of
adding capecitabine and oxaliplatin, administered at
fixed doses according to a schedule previously developedP
Lost to Follow up Survived Lost to Follow up
0 9 0
3 3 3
ogression within the following three years.
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radiation of multiple metastatic lesions in patients with
mCRC.
There are several limitations of the study with respect
to the efficacy caused by the inhomogenous characteris-
tics of patients, the patients (pre)treatment with the
first-, second- or third-line therapy and incomplete in-
formation of local lesions and distant metastases of
patients with progressive disease.
Notwithstanding the trial had to be closed due to re-
cruitment failure, and the small sample size limits con-
clusions. However, the data are promising with regard to
the results of the present trial and should stimulate more
intense investigations to establish the best treatment
regimens to obtain better approaches in the therapy of
oligometastatic colorectal cancer. Moreover, more
advanced radiotherapy techniques (e.g. IGRT, stereotac-
tic radiotherapy and radiosurgery) are now widely avail-
able and 3D-CRT is not considered as contemporary
standard for radiotherapy to metastatic lesions in a po-
tentially curative setting. Nevertheless, our results might
be helpful because they demonstrate the feasibility of a
concurrent chemoradiotherapy approach in this subset
of patients and there are so far few data on the question
of sequencing local and systemic therapy in metastatic
patients.
Conclusions
The results of this phase I study support the use of local
radiotherapy to metastatic lesions in addition to concur-
rent standard chemotherapy as an effective and feasible
therapeutic option in patients with oligometastatic colo-
rectal cancer.
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